Price | 1784€+ |
Organism | Human |
Product Type | Tissue derived organoid |
Tissue | Bile duct |
Disease | Cholangiocarcinoma |
Applications
Toxicity
Small molecules
mRNA
Antibody
Cancer vaccine
Immune Cells
Immuno Oncology with TME
Cytotoxic T cell
TIL (Tumor infiltrating lymphocytes)
Regulatory T cell
Macrophage
CAF (Cancer associate fibroblast)
Cholangiocarcinoma is a cancer with no distinct early symptoms, making early detection challenging, and its exact pathogenesis remains unclear. In Western countries, it is classified as a rare cancer due...
Our Cholangiocarcinoma organoids exhibit high pathological similarity to patient-derived tumor tissues, expressing key Cholangiocarcinoma markers such as CK7, CEA and CA19-9.
Immunohistochemistry (IHC) analyses confirm that these markers are expressed in the organoids in patterns consistent with primary tumors, reflecting their differentiation status and histological characteristics.
These pathological marker analyses demonstrate that Cholangiocarcinoma organoids faithfully recapitulate the morphological and molecular features of patient tumors, making them a reliable platform for cancer pathology research, drug development, and personalized therapy evaluation.
The cholangiocarcinoma (CCA) organoid platform provides a physiologically relevant model that reflects the genetic characteristics of patient tumors.
Whole Exome Sequencing (WES) has been performed on the organoid library, identifying key driver mutations commonly found in CCA.
These genomic profiles are visualized using Oncoplots, providing clear interpretation of the genetic features of each organoid model.
With WES data already established, cancer organoids harboring specific gene mutations can be selectively utilized for targeted drug testing, mechanistic studies, and mutation-driven drug response analysis.
CCA organoids serve as versatile models that reflect diverse tumor characteristics such as metastasis, treatment resistance, and drug sensitivity, making them effective for evaluating both standard therapies and novel anticancer strategies.
This platform supports mutation-specific organoid selection and testing, positioning it as a powerful tool for precision oncology and the development of personalized cancer therapies.
A tailored solution for evaluating the efficacy and resistance of new drugs is available using an established cholangiocarcinoma (CCA) organoid library.
By leveraging comprehensive drug sensitivity data, the most suitable organoid lines are selected based on the characteristics of the investigational drug, enabling precise and reliable drug testing.
Drug sensitivity tests have been conducted using Gemcitabine, Cisplatin, Paclitaxel and 5-FU which are widely used in clinical cancer treatment, and drug response data has been collected from a subset of CCA organoid models, comprising over 10 distinct lines.
This dataset continues to expand as additional testing is performed.
This organoid-based drug sensitivity testing platform enhances the efficiency and reliability of the drug development process and contributes to the advancement of personalized cancer treatment strategies.
Interested in bringing cholangiocarcinoma organoids into your research?
Contact Lambda Biologics to discuss your project with our team.
A Cholangiocarcinoma organoid is a three-dimensional mini-tumor model derived from patient bile duct cancer tissues. These organoids preserve the genetic, histological, and functional characteristics of the original Cholangiocarcinoma, enabling researchers to study tumor biology and evaluate therapeutic responses in a physiologically relevant in vitro system.
Cholangiocarcinoma organoids are generated by isolating tumor cells from surgical or biopsy specimens of Cholangiocarcinoma patients. The cells are embedded in an extracellular matrix scaffold and cultured with defined growth factors that support bile duct epithelial cell growth. Over time, the cells self-organize into 3D organoid structures that replicate key features of the original tumor.
Cholangiocarcinoma organoids are widely used for drug screening, precision oncology, and tumor biology studies. Because they retain patient-specific mutations such as alterations in FGFR2 or IDH1, these models allow researchers to evaluate targeted therapies and identify personalized treatment strategies.
Compared with traditional 2D cell cultures, organoid models better recapitulate tumor architecture, cellular heterogeneity, and treatment response of Cholangiocarcinoma. This makes them powerful tools for predictive drug testing, biomarker discovery, and preclinical evaluation of novel therapeutics.
Simply contact Lambda Biologics team. Our scientists will review your project needs and provide the right options whether it’s technical guidance, a quote, or custom organoid development.
